NOTICE 1 페이지

NEWS & EVENT

Total 12 - 1 page

No	Subject	Date	Hit
12	Ildong Pharmaceutical Invests KRW 13,000,000,000 in iLeadBMS to Strengthen the Ecosystem of Novel Drug R&D	2021.07.15	7,004
익명 7,004 2021.07.15
11	iLeadBMS Announces Results of TPD Molecular Glue Research of IL2106 (CDK12 Molecular Glue and Cyclin-K degrader) at ESMO TAT 2024	2024.02.27	3,973
익명 3,973 2024.02.27
10	iLeadBMS’ Cyclin-K Molecular Glue Receives ODD from FDA for Gastric Cancer	2024.10.07	3,556
익명 3,556 2024.10.07
9	Ildong Pharmaceutical Group’s ‘iLeadBMS’ Presents Non-Clinical Results of its Novel NASH Drug Candidate at the AASLD	2022.11.09	3,186
익명 3,186 2022.11.09
8	iLeadBMS Announces Positive Preclinical Results of IL1512 (CXCR7 Agonist) at the ATS 2024	2024.05.21	3,065
익명 3,065 2024.05.21
7	iLeadBMS Presents Preclinical Data on IL21120033, a First-in-Class ACKR3 Ago-PAM at EULAR 2025	2025.06.14	2,972
익명 2,972 2025.06.14
6	iLeadBMS Announces Positive Liver Fibrosis Results of IL1512 (CXCR7 Agonist) at the EASL 2024	2024.07.10	2,752
익명 2,752 2024.07.10
5	iLeadBMS Announces Orphan Drug Designation Granted by the FDA for IL21120033 (CXCR7 Agonist) for Idiopathic Pulmonary Fibrosis	2025.02.13	2,675
익명 2,675 2025.02.13
4	iLeadBMS Presents Preclinical Data on IL21120033 for Heart Failure at ACC 2025	2025.03.31	2,522
익명 2,522 2025.03.31
3	iLeadBMS Presents Preclinical Data on Novel Drug Candidate for Heart Failure at AFDD	2024.11.21	2,326
익명 2,326 2024.11.21
2	신주발행공고	2025.12.29	1,304
익명 1,304 2025.12.29
1	신주발행공고	2026.03.12	1,078
익명 1,078 2026.03.12

1페이지

INVESTORS & MEDIA

INVESTORS & MEDIA

NEWS & EVENT